To ensure balanced baseline tumor burdens, mice were stratified into groups with comparable hCD45+% in their bone marrows, received anti-CCRL2 ADC or conjugated IgG2a (intravenously, 1 mg/kg) and harvested at day 55 (Fig. 7A). Here, CCRL2 is linked to neoplasm.